Table 2.
Reported cases of de novo MN after COVID-19 vaccination.
| Authors | Age | sex | PMH | Timeline of symptom onset | Type of Vaccine | Begin of symptoms | Laboratory features | treatment | outcome |
|---|---|---|---|---|---|---|---|---|---|
| Fenoglio et al. | 82 | M | N | after 2nd dose | mRNA | NS | Renal biospy: MN | rituximab | NA |
| 67 | F | N | after 2nd dose | mRNA | NS | Renal biospy: MN | rituximab | NA | |
| 82 | F | N | after 2nd dose | mRNA | NS | Renal biospy: MN | Steroid | NA | |
| Caza et al. | 54 | M | NA | 1 days after 2nd dose | mRNA | NS | Scr:1.3; Proteinuria :3+ ALB:3.4; Hematuria:positive Renal biospy: MN |
Steroid; Rituximab | NR |
| 68 | M | NA | 4 wk after 1st dose | Viral vector | NS;AKI; CKD | Scr:3.3; Proteinuria:0.6 ALB:3.2; Renal biospy: MN |
diuretic | NR | |
| 47 | M | NA | 6 days after 2 nd dose | mRNA | NS | Scr:0.7;Proteinuria:2.7 ALB:2.3; Hematuria:positive Renal biospy: MN |
N | PR | |
| Thammathiwat et al. | 53 | M | N | 1 wk after 1st dose | Inactivated | Intermittent lower extremity edema; foamy urine | Scr: 1.5 mg/dL;Proteinuria:3+ RBC:2+; ALB :2.3 g/dL; UPCR:13.4 g/g; Renal biospy: MN |
Steroid; immunosuppressive | CR |
| Da et al. | 70 | M | N | 1 wk after 1st dose | mRNA | generalized edema | ALB: 1.7g/L; Scr:1.29mg/dL; cholesterol :9.24mmol/L; Renal biospy: MN | Irbesartan; diuretic; warfarin | NR |
| Klomjit et al. | 50 | F | NA | 4 wk after 2nd dose | mRNA | Joint pain proteinuria | Scr:0.7mg/dL; protein:6.5 g/d RBC:3-10 /HPF; ALB:3.5g/dl |
Conservative | R |
| Gueguen et al. | 76 | M | HTP; UV-treated cutaneous mycosis fungoid | 4days after 1st dose | mRNA | edema | ALB: 1.6g/L Scr:0.86mg/dL |
rituximab | PR |
| Rashid et al. | 56 | M | HTP | 1 month after 1st dose | mRNA | Fatigue; exertional dyspnea; lower urinary tract symptoms | Scr:13.96mg/dL ALB: 2.2g/L Hematuria:2+ Renal biopsy : MN with positive PLA2R |
Rituximab; HD | R |
| Psyllaki et al. | 68 | M | N | 1 wk after 1st dose | mRNA | lower extremities edema | ALB: 2.9g/L eGFR 70 mL/min/1.73 m2 Renal biopsy : MN with positive PLA2R |
Rituximab | PR |
| Chavarot et al. | 66 | M | HTP;Left nephrectomy; | 8 wk after 2nd dose | mRNA | NA | Scr:1.36mg/dL immunohistochemistry:MN | Conservative | NA |
| Paxton et al. | 22 | M | eczema epilepsy | 1 month after 2nd dose | mRNA | lower limb oedema lethargy | Scr:0.72mg/dL;ALB: 8g/L Proteinuria: 7 g/d UPCR:700.4 mg/mmol Renal biopsy : MN with positive PLA2R |
Rituximab | PR |
| Saigal et al. | 32 | M | NA | 2 wk after dose | Viral vector | NS | NA | Steroid; cyclophosphamide | PR |
| 47 | M | NA | 11 days after dose | Viral vector | Isolated proteinuria | NA | RASi | CR | |
| Fornara et al. | 52 | F | NA | 49 days after dose | mRNA | NA | Scr:0.6mg/dL | RASi | stable |
| GARG et al. | 50 | F | N | 5 wk after 2nd dose | mRNA | edema; proteinuria | Proteinuria:8,720 mg/g; Rena biopsy:MN (NELL-1 positive) | conservative | R |
F, female; M, male;membranous nephropathy,MN; HTP, hypertension; AKI, acute kidney injury; CKD, Chronic Kidney Disease; NS, nephrotic syndrome;Scr, Serum creatinine; ALB, serum albumin; RBC, red blood cell; UTP,24-hurine protein;UPCR,urine protein-to-creatinine ratio; HD, hemodialysis; RASi, renin-angiotensin-aldosterone system inhibition;N,none; CR, complete remission; PR, partial remission; NA, non-applicable; NR, no response;R, response.